ET-traps limited was founded in 2015. Our technology focuses on sequestering pathologically elevated levels of Endothelin-1 in different diseases.

Our venture is developing a therapeutic targeting elevated endothelin-1 levels that may be used in different cancers, neurodegenerative diseases, cardiovascular diseases, diabetes and pregnancy disorders.

After winning the biotech competition, organised by the Judge Business School, University of Cambridge (in association with AstraZeneca, UK), we were able to secure Angel investment and proceed with taking ET-traps Limited forward. 

​

We have performed binding assays* that confirmed the solubility of our ET-trap construct and that it is a very potent binder to endothelin-1, with a binding affinity in the pico molar range.

​

We have also performed PoC studies* in the diabetes disease space, which show that the ET-traps potently and significantly ameliorate disease pathology.

​

Furthermore, our PoC work (both in vitro and in vivo) has shown that ET-traps are non- toxic or cytotoxic at the working concentration, which gives an efficacious effect.